of HCQ was also compared with that of ZDV, a nucleoside reverse transcriptase inhibitor, in a randomized, placebo-controlled clinical trial conducted on 72 HIV-l-infected asymptomatic patients. All subjects were treated for 16 weeks with 800 mg/day HCQ (n = 35) or 500 m